FDA grants accelerated approval to selpercatinib for lung cancer

The U.S. Food and Drug Administration (FDA) has granted accelerated approval to savolitinib, manufactured by Bayer, as a first-line treatment for adults with advanced or metastatic non-small cell lung cancer (NSCLC) whos
Translated by Alqyas from Al-Qabas — Original source
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to savolitinib, manufactured by Bayer, as a first-line treatment for adults with advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors harbor activating HER2 mutations. This approval is based on the results of the Phase 1/2 SOHO-01 trial, which included 69 previously untreated patients. The objective response rate was 75%, comprising complete responses in 6% of patients and partial responses in 70%. Among responders, 73% maintained their response for at least six months. Savolitinib is an oral targeted therapy that works by inhibiting HER2 mutations associated with the growth of cancer cells. In November 2025, the FDA had already granted accelerated approval to savolitinib for the treatment of patients with advanced HER2-mutated NSCLC who had previously received treatment. The new approval comes amid limited treatment options for this patient population, as HER2 mutations are present in approximately 2% to 4% of advanced NSCLC cases. NSCLC is the most common type of lung cancer, accounting for more than 85% of all cases.